---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-011198"
form_type: "8-K"
ticker: null
cik: "0001358403"
company_name: "BELLICUM PHARMACEUTICALS, INC"
filed_at: "2023-04-11T23:59:59+00:00"
generated_at: "2026-06-17T03:34:14.580643+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bellicum receives dual Nasdaq deficiency notices for equity and bid price

## Summary
- Stockholders' equity below Nasdaq Capital Market requirement of $2.5M per April 6 notice; 45 days to submit compliance plan.
- Bid price closed below $1.00 for 30 consecutive days as of April 10; 180 days to regain compliance.
- If bid price falls to $0.10 or less for 10 straight days, immediate delisting may occur.
- Company evaluating options but cannot assure compliance will be achieved.

## SEC filing metadata
- accession: 0001628280-23-011198
- form_type: 8-K
- cik: 0001358403
- company_name: BELLICUM PHARMACEUTICALS, INC
- filed_at: 2023-04-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358403/000162828023011198/0001628280-23-011198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358403/000162828023011198/blcm-20230406.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-011198
- JSON: https://secwatch.observer/filing/0001628280-23-011198.json
- Plain text: https://secwatch.observer/filing/0001628280-23-011198.txt

## Key facts
- Listing & Compliance Notices
  BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: April 10, 2023 Nasdaq Notice On April 10, 2023, the Company received notice (the “Bid Price Notice”) from Nasdaq advising the Company that for 30 consecutive trading days preceding the date of the Bid Price Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company has 180 calendar days from the date of the Bid Price Notice to regain compliance with the Minimum Bid Price Requirement. If at any time during
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023011198/0001628280-23-011198-index.htm
- Listing & Compliance Notices
  BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: April 6, 2023 Nasdaq Notice On April 6, 2023, Bellicum Pharmaceuticals, Inc. (the “Company”) received notice (the “Stockholder’s Equity Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1). The Company has 45 calendar days from the date of the Stockholders’ Equity Notice to submit to Nasdaq a plan to regain compliance. The Company is currently eval
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023011198/0001628280-23-011198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.